Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RCKT |
---|---|---|
09:32 ET | 14972 | 12.75 |
09:33 ET | 15983 | 12.7774 |
09:35 ET | 12626 | 12.81 |
09:37 ET | 18892 | 13.0081 |
09:39 ET | 200 | 13.02 |
09:42 ET | 4800 | 13.185 |
09:44 ET | 8022 | 13.225 |
09:46 ET | 5299 | 13.345 |
09:48 ET | 300 | 13.37 |
09:50 ET | 4586 | 13.3723 |
09:51 ET | 600 | 13.3497 |
09:53 ET | 8358 | 13.4 |
09:55 ET | 4528 | 13.3798 |
09:57 ET | 485 | 13.46 |
10:00 ET | 8208 | 13.4352 |
10:02 ET | 2133 | 13.35 |
10:04 ET | 6086 | 13.4499 |
10:06 ET | 3240 | 13.41 |
10:08 ET | 3254 | 13.405 |
10:09 ET | 4205 | 13.47 |
10:11 ET | 800 | 13.43 |
10:13 ET | 908 | 13.44 |
10:15 ET | 3069 | 13.475 |
10:18 ET | 1700 | 13.47 |
10:20 ET | 2487 | 13.47 |
10:22 ET | 2504 | 13.48 |
10:24 ET | 2450 | 13.44 |
10:26 ET | 6320 | 13.44 |
10:27 ET | 3906 | 13.41 |
10:29 ET | 2900 | 13.395 |
10:31 ET | 700 | 13.37 |
10:33 ET | 22280 | 13.28 |
10:36 ET | 700 | 13.295 |
10:38 ET | 1518 | 13.29 |
10:40 ET | 1336 | 13.32 |
10:42 ET | 600 | 13.385 |
10:44 ET | 200 | 13.385 |
10:45 ET | 500 | 13.42 |
10:47 ET | 300 | 13.41 |
10:49 ET | 2191 | 13.43 |
10:51 ET | 500 | 13.42 |
10:54 ET | 200 | 13.42 |
10:56 ET | 4379 | 13.485 |
10:58 ET | 20124 | 13.54 |
11:00 ET | 5531 | 13.5998 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Rocket Pharmaceuticals Inc | 1.2B | -4.9x | --- |
Pharvaris NV | 1.1B | -8.0x | --- |
Enliven Therapeutics Inc | 1.2B | -13.6x | --- |
Mesoblast Ltd | 1.1B | -11.6x | --- |
ARS Pharmaceuticals Inc | 1.3B | -26.8x | --- |
Applied Therapeutics Inc | 1.1B | -6.1x | --- |
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.2B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 91.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.01 |
EPS | $-2.75 |
Book Value | $5.46 |
P/E Ratio | -4.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.